NS
NSIS-B.CO Novonesis (Novozymes) A/S
- Market cap
- DKK 219B
- P/E
- 40.5x
- P/B
- 2.28x
- ROE
- 6.6%
- Dividend yield
- 1.42%
- Fundamental score
- 2.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is NSIS-B.CO undervalued?
Graham numberNSIS-B.CO trades 102.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novonesis (Novozymes) A/S fundamental analysis
10 of 22 checks passedROE 0/2
Low return on equity (6.6%), below 10%.
ROA 1/1
Return on assets (4.5%) is above the industry median (4.2%).
Profit Consistency 2/2
Profitable for 10 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (87.9%) is above the 5-year average (-34.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (87.9%) is above the industry median (-1.9%).
Revenue Growth 2/2
Revenue grew 20.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (27.5%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 13.6x against interest expense, well covered.
PE vs Market 0/1
PE (46.2x) is above the market median (17.0x).
PE vs Industry 0/1
PE (46.2x) is above the industry median (12.5x).
PBV 0/1
Price to book (2.6x) is above the industry median (1.1x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 120.2, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
Dividend yield (1.5%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 69.1%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Novonesis (Novozymes) A/S stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricult…
Full company profileNovonesis (Novozymes) A/S financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novonesis (Novozymes) A/S annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.1B | 14.5B | 14.4B | 14.4B | 14.0B | 15.0B | 2.36B | 17.9B | 3.83B | 4.15B | 4.47B |
| Gross Profit | 8.17B | 8.43B | 8.30B | 7.99B | 7.85B | 1.16B | 1.29B | 9.72B | 1.81B | 2.24B | 2.51B |
| Operating Income | 4.00B | 4.12B | 4.16B | 3.59B | 3.65B | 4.01B | 621M | 4.55B | 658M | 882M | 1.05B |
| EBITDA | 4.93B | 5.09B | 5.10B | 4.58B | 4.85B | 5.40B | 2.08B | 5.47B | 1.04B | 1.39B | 1.66B |
| Net Income | 3.05B | 3.12B | 3.23B | 3.15B | 2.83B | 3.15B | 493M | 3.02B | 306M | 583M | 741M |
| EPS | 10 | 10 | 11 | 11 | 10 | 11 | 1.77 | 11 | 0.66 | 1.25 | 1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 18.7B | 18.4B | 19.7B | 20.4B | 20.5B | 24.8B | 28.0B | 28.4B | 15.2B | 16.3B | 16.6B |
| Total Liabilities | 6.91B | 7.11B | 8.26B | 8.96B | 9.27B | 12.6B | 13.8B | 14.0B | 4.02B | 5.49B | 5.48B |
| Shareholders' Equity | 11.7B | 11.3B | 11.4B | 11.5B | 11.2B | 11.8B | 13.8B | 14.0B | 11.2B | 10.9B | 11.2B |
| Cash & Short-term Investments | 812M | 632M | 723M | 711M | 1.30B | 1.04B | 1.12B | 1.16B | 284M | 296M | 314M |
| Total Debt | 1.80B | 2.27B | 3.26B | 4.54B | 522M | 482M | 6.95B | 7.78B | 1.80B | 22.4B | 3.07B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 3.84B | 4.06B | 3.68B | 3.20B | 4.36B | 4.06B | 4.01B | 4.15B | 1.02B | 1.22B | 1.05B |
| Capital Expenditure | 1.08B | 1.59B | 1.33B | 862M | 940M | 1.24B | 2.89B | 2.06B | 360M | 471M | 355M |
| Free Cash Flow | 2.76B | 2.47B | 2.35B | 2.33B | 3.42B | 2.82B | 1.12B | 2.10B | 660M | 751M | 691M |
| Ratios | |||||||||||
| ROE | 26.0% | 27.7% | 28.2% | 27.5% | 25.1% | 26.6% | 3.6% | 21.6% | 2.7% | 5.4% | 6.6% |
| ROA | 16.3% | 17.0% | 16.4% | 15.4% | 13.8% | 12.7% | 1.8% | 10.7% | 2.0% | 3.6% | 4.5% |
| Net Profit Margin | 21.6% | 21.5% | 22.4% | 21.9% | 20.2% | 21.0% | 20.9% | 16.9% | 8.0% | 14.0% | 16.6% |
| Debt to Equity | 0.15x | 0.20x | 0.29x | 0.40x | 0.05x | 0.04x | 0.50x | 0.56x | 0.16x | 2.07x | 0.28x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novonesis (Novozymes) A/S dividends
- Dividend yield
- 1.42%
- Forward dividend
- 6.60 DKK
- Payout ratio
- 69.1%
- Ex-dividend date
- Aug 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 403M | 0.86 | 69.1% |
| 2024 | EUR 250M | 0.54 | 81.8% |
| 2023 | DKK 2.86B | 10 | 94.4% |
| 2022 | DKK 1.53B | 5.47 | 309.1% |
| 2021 | DKK 1.47B | 5.23 | 46.6% |
| 2020 | DKK 1.48B | 5.26 | 52.5% |
| 2019 | DKK 1.44B | 5.02 | 45.6% |
| 2018 | DKK 1.32B | 4.50 | 40.8% |
| 2017 | DKK 1.19B | 4.01 | 38.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Nov 28, 2011.
Who owns Novonesis (Novozymes) A/S
- Insiders 15.81%
- Institutions 37.45%
- Public & others 46.75%
- Shares outstanding 413M
- Free float 348M
Novonesis (Novozymes) A/S company profile
- Company name
- Novonesis (Novozymes) A/S
- Ticker
- NSIS-B.CO
- ISIN
- DK0060336014
- Exchange
- Copenhagen Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 10,933
- Fiscal year end
- December
- Address
- Biologiens Vej 2, Lyngby, Denmark, 2800
- Phone
- 45 44 46 00 00
- Website
- novonesis.com
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The company also offers bioenergy solutions including biodiesel; biogas from agricultural and industrial residues and food waste; biomass; carbon capture; ethanol for liquefaction, saccharification, fermentation, and fiber conversion; and renewable diesel. In addition, it provides dishwashing, home cleaning, laundry, medical, and industrial and institutional cleaning services; gastrointestinal, immune, mental, women's, children's cardiometabolic, and oral human health solutions. Further, the company offers corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; silage, diary and beef cattle, poultry, swine, aquaculture solutions; pet care solutions; leather and textiles solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions; and distilling, oils and fats, sustainable plastic solutions. Additionally, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S is headquartered in Lyngby, Denmark.
Novonesis (Novozymes) A/S management
10- Ms. Ester BaigetPresident & CEO · born 1971
- Mr. Rainer LehmannExecutive VP & CFO · born 1975
- Mr. Anders LundChief Operating Officer · born 1973
- Mr. Claus Crone FuglsangChief Scientific Officer · born 1968
- Mr. Tobias Cornelius BjorklundHead of Investor Relations
- Mr. Morten Enggaard RasmussenExecutive Vice President of People & Stakeholder Relations · born 1976
- Mr. Tue MicheelsenPresident of Novonesis North America & Head of Global Consumer Health
- Ms. Tina Sejersgaard FanoExecutive Vice President of Planetary Health Biosolutions · born 1969
- Mr. Henrik Joerck NielsenEVP of Human Health Biosolutions and Strategy & Integration · born 1978
- Mr. Andrew TaylorExecutive Vice President of Food & Beverage Biosolutions